Related Experiment Video
Updated: Jun 3, 2026
08:47
Opsonophagocytic Killing Assay to Assess Immunological Responses Against Bacterial Pathogens
Published on: April 5, 2019
[Immunization against pneumococci with conjugate vaccine].
1Service de pédiatrie, université Paris-XIII, hôpital Jean-Verdier, AP-HP, 93140 Bondy. joel.gaudelus@jvr.aphp.fr
La Revue Du Praticien
|March 24, 2011
Summary
Pneumococcal conjugate vaccine coverage is high for infants but low for boosters. While invasive pneumococcal disease decreased in infants, overall incidence remains unchanged due to serotype shifts.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Epidemiology
Context:
- General recommendation of Pneumococcal conjugate vaccine for infants under two years.
- Satisfactory primovaccination coverage (85%+) with a 2+1 schedule.
- Low booster coverage and delayed administration (14.5 months vs. 12 months).
Purpose:
- Evaluate the impact of Pneumococcal conjugate vaccine on infant immunization rates and disease incidence.
- Analyze changes in pneumococcal serotype distribution post-vaccination.
- Assess the effectiveness of the updated Prevenar 13 vaccine.
Summary:
- Pneumococcal conjugate vaccine (PCV) shows high infant vaccination rates but suboptimal booster uptake.
- Invasive pneumococcal diseases (IPD) decreased in infants by 3% but overall incidence is stable.
- Serotype distribution has shifted, with increased prevalence of serotypes 19A, 7F, and 1.
- Prevenar 13, with six additional serotypes, replaces the 7-valent vaccine, maintaining the 2+1 schedule.
Impact:
- Direct and indirect protection against pneumococcal strains, reducing disease transmission.
- Benefits extend to pneumonia, otitis media, and antibiotic resistance.
- Ongoing epidemiological surveillance is crucial for monitoring serotype replacement and vaccine effectiveness.
Related Concept Videos
01:27Streptococcal Pharyngitis
Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:51Vaccinations
Overview
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following: